Deep brain stimulation for parkinson's disease and neurological movement disorders: a review of the clinical and cost-effectiveness and guidelines
Canadian Agency for Drugs and Technologies in Health
Record ID 32011001164
English
Authors' recommendations:
No literature is available comparing the clinical and cost-effectiveness of rechargeable versus non-rechargeable DBS systems in the management of Parkinson’s disease and neurological movement disorders. Moreover, there is a dearth of primary studies evaluating the efficacy and safety of DBS for movement disorders for the development of practice guidelines. The clinical practice guidelines agree that the data to support the use of DBS is limited in quantity and quality. All, however, recommend the use of DBS among patients who do not achieve adequate control of motor fluctuations and dyskinesia with best medical therapy, who have medication-refractory tremor, or who are intolerant of medical therapy. The current available data suggests DBS can relieve symptoms and improve the overall functioning and quality of life of the patient. Unlike respective ablative therapy, DBS is reversible and it allows titration of stimulation parameters and may be associated with less morbidity.
Details
Project Status:
Completed
Year Published:
2010
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Movement Disorders
- Parkinson Disease
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.